Mobile website
Archive > Volume 30 Issue 6 > 2023,30(6):505-510. DOI:10.3872/j.issn.1007-385X.2023.06.007 Prev Next
Clinical Research
Clinical efficacy and safety of tumor-specific individualized multi-target DC-CIK in the treatment of advanced non-small cell lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the clinical efficacy and safety of tumor-specific individualized multi-target dendritic cell-cytokine-induced killer cell (DC-CIK) in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods: The clinical data of patients with advanced NSCLC who underwent tumor-specific individualized multi-target DC-CIK therapy in the Biotherapy Department of the Eastern Theater General Hospital from October 1, 2019 to October 31, 2022 were retrospectively analyzed. The clinical data and adverse reactions of NSCLC patients were collected. The short-term clinical efficacy was evaluated by the changes of tumor markers in serum before and after the DC-CIK treatment, and the expression of lymphocyte subsets and various cytokines in patients before and after the treatment was detected by flow cytometry. Mass spectrometry was used to detect the changes in the number of targets before and after the treatment. Results: A total of 52 patients with advanced NSCLC were enrolled, including 21 females and 31 males; the age ranged from 32 to 71, with an average age of (50.97±10.72) years old and a median age of 47.5 years old. After DC-CIK treatment, there were 0 cases of CR, 0 cases of PR, 27 cases of SD and 25 cases of PD. Compared with pre-treatment, (1) there was no significant difference in the levels of CEA and CYFRA21-1 after treatment, but the level of CA125 was significantly decreased (P<0.01); (2) there was no significant change in the lymphocyte subsets of patients after treatment; (3) the levels of IL-2, IL-4, IFN-γ, and TNF-α in the peripheral blood of patients were significantly increased (all P<0.01), while the levels of IL-6, IL-10, and IL-17 did not change significantly; (4) the number of targets decreased significantly after treatment. There was no serious adverse reactions occurred during the DC-CIK treatment. Conclusion: Tumor-specific individualized multi-target autologous DC-CIK therapy is safe for patients with advanced NSCLC and can induce anti-tumor immune response in patients, thus bringing clinical benefits.
Keywords:
Project Supported:
Clc Number:
